VEGFA and hereditary clear cell renal cell carcinoma: Our results also are in agreement with the reports of recent clinical trials with111In-bevacizumab in patients with colorectal cancer liver metastases and renal cell carcinoma (RCC) that failed to identify a correlation between uptake of 111In-bevacizumab and VEGF levels measured by ELISA and ISH [18, 27].